Last 12 months
Inside the activity.
9 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 4 | 1 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 4 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 25, 2025 Filed Nov 25, 2025 21:16 UTC |
WIDDER KENNETH JDirector
|
SaleCommon Stock | 4,026 | $27.81 | $111,965.48 |
DisclosureSEC source: 0001065168-25-000005 · wk-form4_1764105367.xml · nonDerivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,061 F1 · price: The weighted average sale price for these transactions was $27.8106 per share, with a range of $27.81 to $27.83. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 21:16 UTC |
WIDDER KENNETH JDirector
|
Exercise / conversionCommon Stock | 7,021 | $15.74 | $110,510.54 |
DisclosureSEC source: 0001065168-25-000005 · wk-form4_1764105367.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 13:21 UTC |
Busky Joseph M.Chief Financial Officer
|
PurchaseCommon Stock | 4,770 | $26.06 | $124,305.25 |
DisclosureSEC source: 0001385091-25-000005 · wk-form4_1764094867.xml · nonDerivative · entry 1 Busky Joseph M. · CIK 0001385091 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 6,920 Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 21:09 UTC |
POLAN MARY LAKE PH DDirector
|
PurchaseCommon Stock | 1,000 | $22.43 | $22,430.00 |
DisclosureSEC source: 0001187716-25-000006 · wk-form4_1764018554.xml · nonDerivative · entry 1 POLAN MARY LAKE PH D · CIK 0001187716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,640 Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 21:16 UTC |
Blaser Brian J.President and CEO
|
PurchaseCommon Stock | 23,500 | $21.34 | $501,576.95 |
DisclosureSEC source: 0001492289-25-000006 · wk-form4_1763673411.xml · nonDerivative · entry 1 Blaser Brian J. · CIK 0001492289 · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 29,533 F1 · price: The weighted average purchase price for these transactions was $21.3437 per share, with a range of $20.91 to $21.72 per share. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 16:18 UTC |
Hodges Michelle AChief Legal Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 5,349 | $0.00 | $0.00 |
DisclosureSEC source: 0001833942-25-000006 · wk-form4_1763673496.xml · derivative · entry 3 Hodges Michelle A · CIK 0001833942 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,698 Underlying: Common Stock · 5,349 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 5,349 shares vested on November 18, 2025; the remaining 10,698 shares will vest in equal installments on November 18, 2026 and November 18, 2027. F4 · derivative.expiration_date: 5,349 shares vested on November 18, 2025; the remaining 10,698 shares will vest in equal installments on November 18, 2026 and November 18, 2027. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 16:18 UTC |
Hodges Michelle AChief Legal Officer
|
Tax withholdingCommon Stock | 2,717 | $21.28 | $57,817.76 |
DisclosureSEC source: 0001833942-25-000006 · wk-form4_1763673496.xml · nonDerivative · entry 2 Hodges Michelle A · CIK 0001833942 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,035 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 16:18 UTC |
Hodges Michelle AChief Legal Officer
|
GrantCommon Stock | 5,349 | $0.00 | $0.00 |
DisclosureSEC source: 0001833942-25-000006 · wk-form4_1763673496.xml · nonDerivative · entry 1 Hodges Michelle A · CIK 0001833942 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,752 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 16:16 UTC |
Siegrist Jonathan PhilipEVP of R&D & CTO
|
Exercise / conversionRestricted Stock Units · Derivative | 18,656 | $0.00 | $0.00 |
DisclosureSEC source: 0002040321-25-000005 · wk-form4_1760732193.xml · derivative · entry 3 Siegrist Jonathan Philip · CIK 0002040321 · EVP of R&D & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,314 Underlying: Common Stock · 18,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 18,656 shares vested on October 15, 2025; the remaining 37,314 shares will vest in equal installments on October 15, 2026 and October 15, 2027. F4 · derivative.expiration_date: 18,656 shares vested on October 15, 2025; the remaining 37,314 shares will vest in equal installments on October 15, 2026 and October 15, 2027. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 16:16 UTC |
Siegrist Jonathan PhilipEVP of R&D & CTO
|
Tax withholdingCommon Stock | 6,676 | $27.31 | $182,321.56 |
DisclosureSEC source: 0002040321-25-000005 · wk-form4_1760732193.xml · nonDerivative · entry 2 Siegrist Jonathan Philip · CIK 0002040321 · EVP of R&D & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,980 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 16:16 UTC |
Siegrist Jonathan PhilipEVP of R&D & CTO
|
GrantCommon Stock | 18,656 | $0.00 | $0.00 |
DisclosureSEC source: 0002040321-25-000005 · wk-form4_1760732193.xml · nonDerivative · entry 1 Siegrist Jonathan Philip · CIK 0002040321 · EVP of R&D & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,656 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 3. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 16:14 UTC |
Hodges Michelle AChief Legal Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 390 | $0.00 | $0.00 |
DisclosureSEC source: 0001833942-25-000005 · wk-form4_1760732072.xml · derivative · entry 3 Hodges Michelle A · CIK 0001833942 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 390 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 390 shares vested on October 15, 2025. F4 · derivative.expiration_date: 390 shares vested on October 15, 2025. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 16:14 UTC |
Hodges Michelle AChief Legal Officer
|
Tax withholdingCommon Stock | 199 | $27.31 | $5,434.69 |
DisclosureSEC source: 0001833942-25-000005 · wk-form4_1760732072.xml · nonDerivative · entry 2 Hodges Michelle A · CIK 0001833942 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,403 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 16:14 UTC |
Hodges Michelle AChief Legal Officer
|
GrantCommon Stock | 390 | $0.00 | $0.00 |
DisclosureSEC source: 0001833942-25-000005 · wk-form4_1760732072.xml · nonDerivative · entry 1 Hodges Michelle A · CIK 0001833942 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,602 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:05 UTC |
Bowman Ronald LeeChief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 2,565 | $0.00 | $0.00 |
DisclosureSEC source: 0002036238-25-000006 · wk-form4_1758139555.xml · derivative · entry 3 Bowman Ronald Lee · CIK 0002036238 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,132 Underlying: Common Stock · 2,565 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 2,565 shares vested on September 15, 2025; the remaining 5,132 shares shares will vest in equal installments on September 15, 2026 and September 15, 2027. F4 · derivative.expiration_date: 2,565 shares vested on September 15, 2025; the remaining 5,132 shares shares will vest in equal installments on September 15, 2026 and September 15, 2027. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:05 UTC |
Bowman Ronald LeeChief Human Resources Officer
|
Tax withholdingCommon Stock | 918 | $28.92 | $26,548.56 |
DisclosureSEC source: 0002036238-25-000006 · wk-form4_1758139555.xml · nonDerivative · entry 2 Bowman Ronald Lee · CIK 0002036238 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,647 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:05 UTC |
Bowman Ronald LeeChief Human Resources Officer
|
GrantCommon Stock | 2,565 | $0.00 | $0.00 |
DisclosureSEC source: 0002036238-25-000006 · wk-form4_1758139555.xml · nonDerivative · entry 1 Bowman Ronald Lee · CIK 0002036238 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,565 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:09 UTC |
BUECHLER KENNETH FDirector
|
Exercise / conversionNon-Qualified Stock Options · Derivative | 9,215 | $0.00 Strike: $15.74 | $0.00 |
DisclosureSEC source: 0001906324-25-000145 · wk-form4_1752782940.xml · derivative · entry 2 BUECHLER KENNETH F · CIK 0001238916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,215 shares Expires 2026-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option award vested in full on May 17, 2017. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:09 UTC |
BUECHLER KENNETH FDirector
|
Exercise / conversionCommon Stock | 9,215 | $15.74 | $145,044.10 |
DisclosureSEC source: 0001906324-25-000145 · wk-form4_1752782940.xml · nonDerivative · entry 1 BUECHLER KENNETH F · CIK 0001238916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:06 UTC |
McLellan Philip D.Chief Operations Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 4,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000138 · wk-form4_1751486794.xml · derivative · entry 3 McLellan Philip D. · CIK 0002045799 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,749 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 4,749 shares fully vested on June 30, 2025. F4 · derivative.expiration_date: 4,749 shares fully vested on June 30, 2025. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:06 UTC |
McLellan Philip D.Chief Operations Officer
|
Tax withholdingCommon Stock | 1,951 | $28.82 | $56,227.82 |
DisclosureSEC source: 0001906324-25-000138 · wk-form4_1751486794.xml · nonDerivative · entry 2 McLellan Philip D. · CIK 0002045799 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,304 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:06 UTC |
McLellan Philip D.Chief Operations Officer
|
GrantCommon Stock | 4,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000138 · wk-form4_1751486794.xml · nonDerivative · entry 1 McLellan Philip D. · CIK 0002045799 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,255 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 3. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 16:08 UTC |
Busky Joseph M.Chief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 21,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000140 · wk-form4_1751486927.xml · derivative · entry 4 Busky Joseph M. · CIK 0001385091 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,367 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 21,367 shares fully vested on June 30, 2025. F4 · derivative.expiration_date: 21,367 shares fully vested on June 30, 2025. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 16:08 UTC |
Busky Joseph M.Chief Financial Officer
|
Tax withholdingCommon Stock | 9,883 | $28.82 | $284,828.06 |
DisclosureSEC source: 0001906324-25-000140 · wk-form4_1751486927.xml · nonDerivative · entry 2 Busky Joseph M. · CIK 0001385091 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,427 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 16:08 UTC |
Busky Joseph M.Chief Financial Officer
|
GrantCommon Stock | 21,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000140 · wk-form4_1751486927.xml · nonDerivative · entry 1 Busky Joseph M. · CIK 0001385091 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,310 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 16:10 UTC |
Hodges Michelle AChief Legal Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 11,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000142 · wk-form4_1751487052.xml · derivative · entry 3 Hodges Michelle A · CIK 0001833942 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,873 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 11,873 shares fully vested on June 30, 2025. F4 · derivative.expiration_date: 11,873 shares fully vested on June 30, 2025. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 16:10 UTC |
Hodges Michelle AChief Legal Officer
|
Tax withholdingCommon Stock | 6,030 | $28.82 | $173,784.60 |
DisclosureSEC source: 0001906324-25-000142 · wk-form4_1751487052.xml · nonDerivative · entry 2 Hodges Michelle A · CIK 0001833942 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,212 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 16:10 UTC |
Hodges Michelle AChief Legal Officer
|
GrantCommon Stock | 11,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000142 · wk-form4_1751487052.xml · nonDerivative · entry 1 Hodges Michelle A · CIK 0001833942 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,242 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 16:03 UTC |
Busky Joseph M.Chief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 5,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000133 · wk-form4_1748981026.xml · derivative · entry 4 Busky Joseph M. · CIK 0001385091 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,392 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 5,391 shares vested on June 1, 2023, 5,391 shares vested on June 1, 2024, and 5,392 shares vested on June 1, 2025. F4 · derivative.expiration_date: 5,391 shares vested on June 1, 2023, 5,391 shares vested on June 1, 2024, and 5,392 shares vested on June 1, 2025. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 16:03 UTC |
Busky Joseph M.Chief Financial Officer
|
Tax withholdingCommon Stock | 2,466 | $30.67 | $75,632.22 |
DisclosureSEC source: 0001906324-25-000133 · wk-form4_1748981026.xml · nonDerivative · entry 2 Busky Joseph M. · CIK 0001385091 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,943 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 16:03 UTC |
Busky Joseph M.Chief Financial Officer
|
GrantCommon Stock | 5,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000133 · wk-form4_1748981026.xml · nonDerivative · entry 1 Busky Joseph M. · CIK 0001385091 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,409 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:20 UTC |
WIDDER KENNETH JDirector
|
GrantRestricted Stock Units (Premium) · Derivative | 878 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000124 · wk-form4_1748895637.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 878 Underlying: Common Stock · 878 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:20 UTC |
WIDDER KENNETH JDirector
|
GrantRestricted Stock Units (Converted) · Derivative | 2,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000124 · wk-form4_1748895637.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,926 Underlying: Common Stock · 2,926 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: 731 shares vested on May 29, 2025, 731 shares will vest on August 29, 2025, 732 shares will vest on November 29, 2025 and 732 shares will vest on February 28, 2026. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: 731 shares vested on May 29, 2025, 731 shares will vest on August 29, 2025, 732 shares will vest on November 29, 2025 and 732 shares will vest on February 28, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:20 UTC |
WIDDER KENNETH JDirector
|
GrantRestricted Stock Units (Equity Grant) · Derivative | 6,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000124 · wk-form4_1748895637.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,829 Underlying: Common Stock · 6,829 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:22 UTC |
Chiminski John RDirector
|
GrantRestricted Stock Units (Premium ) · Derivative | 487 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000126 · wk-form4_1748895750.xml · derivative · entry 3 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 487 Underlying: Common Stock · 487 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:22 UTC |
Chiminski John RDirector
|
GrantRestricted Stock Units (Converted) · Derivative | 2,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000126 · wk-form4_1748895750.xml · derivative · entry 2 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,439 Underlying: Common Stock · 2,439 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: 609 shares vested on May 29, 2025, 610 shares will vest on August 29, 2025, 610 shares will vest on November 29, 2025 and 610 shares will vest on February 28, 2026. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: 609 shares vested on May 29, 2025, 610 shares will vest on August 29, 2025, 610 shares will vest on November 29, 2025 and 610 shares will vest on February 28, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:22 UTC |
Chiminski John RDirector
|
GrantRestricted Stock Units (Equity Grant) · Derivative | 6,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000126 · wk-form4_1748895750.xml · derivative · entry 1 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,829 Underlying: Common Stock · 6,829 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:24 UTC |
BUECHLER KENNETH FDirector
|
GrantRestricted Stock Units (Premium) · Derivative | 1,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000128 · wk-form4_1748895864.xml · derivative · entry 3 BUECHLER KENNETH F · CIK 0001238916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,609 Underlying: Common Stock · 1,609 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:24 UTC |
BUECHLER KENNETH FDirector
|
GrantRestricted Stock Units (Converted) · Derivative | 5,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000128 · wk-form4_1748895864.xml · derivative · entry 2 BUECHLER KENNETH F · CIK 0001238916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,365 Underlying: Common Stock · 5,365 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: 1,341 shares vested on May 29, 2025, 1,341 shares will vest on August 29, 2025, 1,341 shares will vest on November 29, 2025 and 1,342 shares will vest on February 28, 2026. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: 1,341 shares vested on May 29, 2025, 1,341 shares will vest on August 29, 2025, 1,341 shares will vest on November 29, 2025 and 1,342 shares will vest on February 28, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:24 UTC |
BUECHLER KENNETH FDirector
|
GrantRestricted Stock Units (Equity Grant) · Derivative | 6,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000128 · wk-form4_1748895864.xml · derivative · entry 1 BUECHLER KENNETH F · CIK 0001238916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,829 Underlying: Common Stock · 6,829 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:26 UTC |
POLAN MARY LAKE PH DDirector
|
GrantRestricted Stock Units (Premium) · Derivative | 731 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000130 · wk-form4_1748896009.xml · derivative · entry 3 POLAN MARY LAKE PH D · CIK 0001187716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 731 Underlying: Common Stock · 731 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:26 UTC |
POLAN MARY LAKE PH DDirector
|
GrantRestricted Stock Units (Converted) · Derivative | 2,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000130 · wk-form4_1748896009.xml · derivative · entry 2 POLAN MARY LAKE PH D · CIK 0001187716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,439 Underlying: Common Stock · 2,439 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: 609 shares vested on May 29, 2025, 610 shares will vest on August 29, 2025, 610 shares will vest on November 29, 2025 and 610 shares will vest on February 28, 2026. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: 609 shares vested on May 29, 2025, 610 shares will vest on August 29, 2025, 610 shares will vest on November 29, 2025 and 610 shares will vest on February 28, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:26 UTC |
POLAN MARY LAKE PH DDirector
|
GrantRestricted Stock Units (Equity Grant) · Derivative | 6,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000130 · wk-form4_1748896009.xml · derivative · entry 1 POLAN MARY LAKE PH D · CIK 0001187716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,829 Underlying: Common Stock · 6,829 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:11 UTC |
RHOADS ANN DDirector
|
GrantRestricted Stock Units (Premium) · Derivative | 325 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000120 · wk-form4_1748895057.xml · derivative · entry 3 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325 Underlying: Common Stock · 325 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:11 UTC |
RHOADS ANN DDirector
|
GrantRestricted Stock Units (Converted) · Derivative | 1,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000120 · wk-form4_1748895057.xml · derivative · entry 2 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,626 Underlying: Common Stock · 1,626 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: 406 shares vested on May 29, 2025, 406 shares will vest on August 29, 2025, 407 shares will vest on November 29, 2025 and 407 shares will vest on November 29, 2025. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: 406 shares vested on May 29, 2025, 406 shares will vest on August 29, 2025, 407 shares will vest on November 29, 2025 and 407 shares will vest on November 29, 2025. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:11 UTC |
RHOADS ANN DDirector
|
GrantRestricted Stock Units (Equity Grant) · Derivative | 6,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000120 · wk-form4_1748895057.xml · derivative · entry 1 RHOADS ANN D · CIK 0001250252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,829 Underlying: Common Stock · 6,829 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:23 UTC |
Huennekens R ScottDirector
|
GrantRestricted Stock Units (Equity Grant) · Derivative | 6,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000127 · wk-form4_1748895794.xml · derivative · entry 1 Huennekens R Scott · CIK 0001365493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,829 Underlying: Common Stock · 6,829 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:13 UTC |
Strobeck MatthewDirector
|
GrantRestricted Stock Units (Equity Grant) · Derivative | 6,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000122 · wk-form4_1748895176.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,829 Underlying: Common Stock · 6,829 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:14 UTC |
Dilsaver Evelyn SDirector
|
GrantRestricted Stock Units (Equity Grant) · Derivative | 6,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000123 · wk-form4_1748895239.xml · derivative · entry 1 Dilsaver Evelyn S · CIK 0001391387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,829 Underlying: Common Stock · 6,829 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:12 UTC |
Michael Edward L.Director
|
GrantRestricted Stock Units (Premium) · Derivative | 617 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000121 · wk-form4_1748895124.xml · derivative · entry 3 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 617 Underlying: Common Stock · 617 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.